US-based genomic analysis technology developer Centrillion Technologies has announced it has received an undisclosed amount of funding from healthcare services platform WeDoctor, having recently closed a total of $55.6m of funding.
WeDoctor’s contribution was described as a multimillion-dollar investment and came two weeks after regulatory filings showed Centrillion had secured $28m in new funding in addition to increasing a round it began raising in May 2016 to $27.6m.
Founded in 2009, Centrillion is working on genomics sensor chips that are used in biomolecule sequencing analysis to detect DNA, RNA and protein molecules and analyse tissue in biopsies.
The company also oversees what it claims is the only molecular diagnostic laboratory in the US that focuses on eye diseases.
China-headquartered WeDoctor supplied the funding in connection with a strategic cooperation deal that will involve it partnering Centrillion’s Chinese subsidiary to jointly provide DNA chips and genomic analysis services in its home country.
Centrillion has now raised a total of $114m in equity funding according to securities filings. It has not disclosed the identity of any of its other investors.
The WeDoctor deal was disclosed on the same day as Centrillion’s sister company, Centrillion Technologies Taiwan, revealed that it was received an undisclosed amount of funding from Arm IoT Fund, a strategic investment vehicle for semiconductor technology producer Arm.